Ani Pharmaceuticals’ Cook sells $35k in stock

Published 14/08/2025, 23:16
Ani Pharmaceuticals’ Cook sells $35k in stock

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 400 shares of common stock on August 13, 2025, at a price of $88.87, for a total transaction value of $35548.

Following the transaction, Cook directly owns 76474 shares of ANI Pharmaceuticals. The sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024. According to InvestingPro analysis, the stock’s technical indicators suggest overbought conditions, with the company now valued at $1.81 billion. For deeper insights into insider trading patterns and 15+ additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.

In other recent news, ANI Pharmaceuticals reported strong financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted non-GAAP earnings per share (EPS) of $1.80, exceeding FactSet consensus estimates of $1.41, and reported revenue of $211.4 million, which was above the forecast of $187.34 million. This performance was largely driven by the Cortrophin Gel product line, which saw revenue reach $81.6 million, marking a 66% year-over-year growth and a 54% sequential increase from the first quarter of 2025. Following these results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.

Analyst firms have responded positively to these developments. Truist Securities increased its price target for ANI Pharmaceuticals to $77 from $65, maintaining a Hold rating. H.C. Wainwright also raised its price target to $93 from $84, while maintaining a Buy rating. These upgrades reflect the strong performance of the company’s product lines and its revised financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.